Full Press Release Details
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company’s research and operational milestones achieved in 2025 and outlines Zhengye’s strategic priorities for growth in 2026. The full text of the letter follows.
Dear Shareholders,
As we enter 2026, on behalf of the management of Zhengye Biotechnology Holding Limited, I am proud of the milestones we achieved in 2025 and would like to share our strategic vision for 2026 and the years ahead.
In 2025, China’s swine industry continued to consolidate, with large-scale producers gaining market share and raising standards for vaccine quality and technical service. In response, Zhengye strengthened its research and development (“R&D”) activities, achieved regulatory milestones, and strengthened its operational platforms. I am deeply encouraged by what our team accomplished. The milestones we achieved are not just metrics on paper—I believe they represent real competitive advantages that position us to capture meaningful opportunities as China’s swine industry continues to modernize. These achievements position the Company to better serve the evolving needs of large-scale domestic customers while supporting continued expansion in selected international markets.
Core Achievements in 2025: A Year of Strategic Execution and Innovation
Over the past year, we focused on strengthening our innovation capabilities, advancing regulatory milestones, and building operational excellence to capture opportunities in an evolving industry landscape. What guided us through these efforts was our unwavering commitment to becoming a world-leading manufacturer that delivers reliable veterinary vaccines to customers around the world. Every patent filed, every regulatory approval earned, and every capability enhanced represents a deliberate investment in our future competitiveness and our ability to better serve our customers.
1.R&D Innovation and Regulatory Milestones
2.Advancing International Market Expansion
3.Enhanced Production Capabilities and Digital Transformation
4.Other Business Development
5.Nasdaq Listing
Strategic Outlook for 2026: Building on a Foundation of Strength
As we look to 2026, we are encouraged by the signs of gradual recovery of China’s swine market, with industry expectations for a price inflection point around mid-year. More importantly, the capabilities we have built, our expanded product portfolio, strengthened international presence, and enhanced operational platforms provide a solid foundation for our next stage of growth. Building on our foundation, we plan to focus on the following strategic priorities:
1.Deepening Strategic Customer Engagement
2.Strengthening Product Portfolio with Solution-Based Marketing
3.Building an Empowering Customer Service Ecosystem
4.Strategic Expansion into Companion Animal Sector
On behalf of the entire Zhengye team, I extend my deepest appreciation to our shareholders for your unwavering support and trust in our vision. Your confidence enables us to remain focused, disciplined, and committed to building enduring value. Our achievements to date reflect not only the progress we have made, but also the collective effort, perseverance, and sense of responsibility shared across our organization. As we move forward, we remain dedicated to strengthening our capabilities and building a company that earns the trust of customers, partners, and shareholders alike. Together, we intend to continue to advance innovation and growth, and remain firmly committed to delivering sustainable, long-term value for our shareholders.
Sincerely,
Zhenfa HanChairman of the Board of DirectorsZhengye Biotechnology Holding Limited
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three GMP veterinary vaccine production floors (including 13 GMP vaccine production lines), one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of tenure and experience in the veterinary vaccine industry. For more information, please visit the Company’s website:http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact: